Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: Recently diagnosed, drug-naïve patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. RESULTS: Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Persistent improvements were seen in those who completed 4 years of monotherapy and marked deterioration of β-cell function in those who failed to maintain adequate glucose control with initial monotherapy. CONCLUSIONS: The favorable combined changes in β-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This differential effect was largely related to the impact on β-cell function11,138.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“Further progressive deterioration of β-cell function accounts for the evolving natural history of the disease from impaired glucose tolerance to type 2 diabetes10,11.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SNEDECOR, G. W. (1939) · Soil Science · doi:10.1097/00010694-193902000-00006 · Cited by 19,359
Applied Linear Statistical Models
Ziegel, E. R., Neter, J., Wasserman, W., & Kutner, M. (1992) · Technometrics · doi:10.2307/1269588 · Cited by 9,907
Regression Diagnostics: Identifying Influential Data and Sources of Collinearity
Belsley, D. A., Kuh, E., & Welsch, R. E. (1980) · Wiley Series in Probability and Statistics · doi:10.1002/0471725153 · Cited by 7,297
Applied Linear Statistical Models
(1997) · Technometrics · doi:10.1080/00401706.1997.10485141 · Cited by 7,185
Regression Diagnostics -- Identifying Influential Data and Sources of Collinearity
Beaumont, C. D., Belsley, D. A., Kuh, E., & Welsch, R. E. (1981) · The Journal of the Operational Research Society · doi:10.2307/2581267 · Cited by 6,359
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citationKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“This is best demonstrated by the loss of b-cell function over time in individuals who progress from states of impaired glucose metabolism to diabetes (14,15).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 1
- Faulenbach, 2008, Prevalence of negative insulinogenic index by glucose tolerance in three different cohorts, Diabetes, 57, A669
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationChatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Self-citationHampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Young-onset type 2 diabetes mellitus — implications for morbidity and mortality
Magliano, D. J., Sacre, J. W., Harding, J. L., Gregg, E. W., Zimmet, P. Z., & Shaw, J. E. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0334-z · Cited by 483
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“It is now clear that the progressive pancreatic beta-cell defect that drives the deterioration of metabolic control over time begins early and may be present before the diagnosis of T2D (1-3).”
BackgroundTODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
“The ADOPT (A Diabetes Outcome Progression Trial) study of drugnaive adults with type 2 diabetes showed that the insulinogenic index declined at a rate of ;7–11% per year (12).”
BackgroundMethodResultInfluentialAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Jiménez, A., Casamitjana, R., Flores, L., Viaplana, J., Corcelles, R., Lacy, A., & Vidal, J. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318262ee6b · Cited by 237
Cardiometabolic risk in obese children
Chung, S. T., Onuzuruike, A. U., & Magge, S. N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13602 · Cited by 213
Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05245-x · Cited by 192
Self-citationBeta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176
“Furthermore, the lack of a beneficial effect of metformin alone on b-cell function, even when youth were still on the medication at 12 months, contrasts withobservations after 1 year of therapy in adults with IGT (5) or type 2 diabetes (22).”
BackgroundResultSelf-citationISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Shah, A. S., Zeitler, P. S., Wong, J., Pena, A. S., Wicklow, B., Arslanian, S., Chang, N., Fu, J., Dabadghao, P., Pinhas‐Hamiel, O., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13409 · Cited by 170
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
β-Cell function in type 2 diabetes
Ferrannini, E., & Mari, A. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.012 · Cited by 164
The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
Hannon, T. S., & Arslanian, S. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12939 · Cited by 137
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
Bacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00915.x · Cited by 106
“∼16–20% rate of decline per year in the monotherapy failure group (18).”
BackgroundResultInfluentialHandelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
The RISE Consortium (2014) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 100
Youth-Onset Type 2 Diabetes Mellitus: Lessons Learned From the TODAY Study
Narasimhan, S., & Weinstock, R. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.009 · Cited by 95
Saisho, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050744 · Cited by 112
Age-related diseases as vicious cycles
Belikov, A. V. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.002 · Cited by 90
Hannon, T. S., Kahn, S. E., Utzschneider, K. M., Buchanan, T. A., Nadeau, K. J., Zeitler, P. S., Ehrmann, D. A., Arslanian, S. A., Caprio, S., Edelstein, S. L., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13005 · Cited by 87
Self-citationCurrent management of diabetes mellitus and future directions in care
Chatterjee, S., & Davies, M. J. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133200 · Cited by 85
Comparative effectiveness of incident oral antidiabetic drugs on kidney function
Hung, A. M., Roumie, C. L., Greevy, R. A., Liu, X., Grijalva, C. G., Murff, H. J., Ikizler, T. A., & Griffin, M. R. (2012) · Kidney International · doi:10.1038/ki.2011.444 · Cited by 85
The role of beta-cell dysfunction in early type 1 diabetes
Sims, E. K., Mirmira, R. G., & Evans-Molina, C. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000548 · Cited by 77
Arslanian, S. A., Kim, J. Y., Nasr, A., Bacha, F. F., Tfayli, H. M., Lee, S., & Toledo, F. G. S. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12562 · Cited by 82
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Self-citationEarly-onset type 2 diabetes: the next major diabetes transition
Luk, A., Wild, S. H., Jones, S., Anjana, R. M., Hivert, M.-F., McCaffrey, J., Gregg, E. W., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00830-x · Cited by 81
Barrett, T. G., Jalaludin, M. Y., Turan, S., Hafez, M., Shehadeh, N., & Panel, O. B. O. T. N. N. P. T. 2. D. G. E. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12953 · Cited by 73
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 73
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
SHAH, A. S., Pérez, M. B., CHANG, N. T., Fu, J., Hannon, T. S., Kelsey, M. M., Peña, A. S., Pinhas‐Hamiel, O., Urakami, T., Wicklow, B. A., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543033 · Cited by 100
Consensus on the key characteristics of metabolism disruptors
Merrill, M. A. L., Smith, M. T., McHale, C. M., Heindel, J. J., Atlas, E., Cave, M. C., Collier, D. N., Guyton, K. Z., Koliwad, S. K., Nadal, Á., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01059-8 · Cited by 84
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
The Prevalence of Obesity Among Children With Type 2 Diabetes: A Systematic Review and Meta-analysis
Cioana, M., Deng, J., Nadarajah, A., Hou, M., Qiu, Y., Chen, S. S. J., Rivas, A., Banfield, L. E., Toor, P. P., Zhou, F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47186 · Cited by 92
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
Self-citationvan Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 64
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 69
Lamont, B. J., Waters, M. F., & Andrikopoulos, S. (2016) · Nutrition & Diabetes · doi:10.1038/nutd.2016.2 · Cited by 57
Zinc as a Potential Coadjuvant in Therapy for Type 2 Diabetes
Ruz, M., Carrasco, F., Rojas, P., Codoceo, J., Inostroza, J., Basfi-fer, K., Valencia, A., Vásquez, K. Y., Galgani, J. E., Pérez, Á., et al. (2013) · Food and Nutrition Bulletin · doi:10.1177/156482651303400210 · Cited by 63
D'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56
Legaard, G. E., Lyngbæk, M. P. P., Almdal, T., Karstoft, K., Bennetsen, S. L., Feineis, C. S., Nielsen, N. S., Durrer, C. G., Liebetrau, B., Nystrup, U., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00799-7 · Cited by 66
Xie, T., So, W. Y., Li, X. Y., & Leung, P. S. (2019) · Clinical Science · doi:10.1042/cs20190093 · Cited by 58
Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models
Powell, D. R., DaCosta, C. M., Smith, M. G., Doree, D. D., Harris, A. L., Buhring, L., Heydorn, W. E., Nouraldeen, A. M., Xiong, W., Yalamanchili, P., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214304 · Cited by 58
Novel approaches to restore beta cell function in prediabetes and type 2 diabetes
Salunkhe, V. A., Veluthakal, R., Kahn, S. E., & Thurmond, D. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4658-3 · Cited by 65
Self-citationHarada, S., Fujita‐Hamabe, W., & Tokuyama, S. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r04cr · Cited by 57
Evaluation and Treatment of Prediabetes in Youth
Magge, S. N., Silverstein, J. H., Elder, D. A., Nadeau, K. J., & Hannon, T. S. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.061 · Cited by 62
Galderisi, A., Giannini, C., Weiss, R., Kim, G., Shabanova, V., Santoro, N., Pierpont, B., Savoye, M., & Caprio, S. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30235-9 · Cited by 49
Factors Associated with Beta-Cell Dysfunction in Type 2 Diabetes: The BETADECLINE Study
Russo, G. T., Giorda, C. B., Cercone, S., Nicolucci, A., Cucinotta, D., & on behalf of BetaDecline Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0109702 · Cited by 49
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 54
Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need
Yang, Y., Han, K., Sohn, T. S., & Kim, N. H. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.379 · Cited by 51
van Raalte, D. H., van Genugten, R. E., Eliasson, B., Möller-Goede, D. L., Mari, A., Tura, A., Wilson, C., Fleck, P. R., Taskinen, M., Smith, U., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0639 · Cited by 49
Nambam, B., Silverstein, J. H., Cheng, P., Ruedy, K. J., Beck, R. W., Wadwa, R. P., KLINGENSMITH, G. J., Willi, S. M., Wood, J., Bacha, F. F., et al. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12377 · Cited by 44
Pan, D., Wang, W., Liu, N., Yang, Q., Zhang, K., Zhu, J.-Z., Shan, S., Li, Z., Ning, Z., Huang, L., et al. (2017) · PPAR Research · doi:10.1155/2017/4313561 · Cited by 46
Zhang, C., Dong, L., Wu, J., Qiao, S., Xu, W., Ma, S., Zhao, B., & Wang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110350 · Cited by 45
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., & Matthews, D. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12508 · Cited by 39
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Bianchi, C., Daniele, G., Dardano, A., Miccoli, R., & Prato, S. D. (2017) · Drugs · doi:10.1007/s40265-017-0694-4 · Cited by 48
Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
Shehadeh, N., Barrett, T. G., Galassetti, P. R., Karlsson, C., Monyak, J. T., Iqbal, N., & Tamborlane, W. V. (2023) · NEJM Evidence · doi:10.1056/evidoa2300210 · Cited by 45
Utzschneider, K. M., Tripputi, M. T., Kozedub, A., Barengolts, E., Caprio, S., Cree‐Green, M., Edelstein, S. L., ghormli, L. K. E., Hannon, T. S., Mather, K. J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108948 · Cited by 39
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 43
Cho, Y., Park, H. S., Huh, B. W., Seo, S., Seo, D. H., Ahn, S. H., Hong, S., Suh, Y. J., & Kim, S. H. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101389 · Cited by 42
Association between beta cell function and future glycemic control in patients with type 2 diabetes
Saisho, Y., Kou, K., Tanaka, K., Abe, T., Shimada, A., Kawai, T., & Itoh, H. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0416 · Cited by 36
Prevention of Type 2 Diabetes in U.S. Hispanic Youth: A Systematic Review of Lifestyle Interventions
McCurley, J. L., Crawford, M. A., & Gallo, L. C. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.05.020 · Cited by 37
Serbis, A., Giapros, V. I., Tsamis, K. I., Balomenou, F., Galli‐Τsinopoulou, A., & Siomou, E. C. (2023) · Nutrients · doi:10.3390/nu15092217 · Cited by 46
Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT)
Chen, M. E., Aguirre, R. S., & Hannon, T. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1023-3 · Cited by 41
Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 48
Kwon, M. J., Lee, Y., Jung, H. S., Shin, H. M., Kim, T. N., Lee, S. H., Rhee, B. D., Kim, M.-K., & Park, J. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.006 · Cited by 34
Pavlidou, E., Papadopoulou, S. Κ., Fasoulas, A., Papaliagkas, V. T., Alexatou, O., Chatzidimitriou, M., Mentzelou, M., & Giaginis, C. (2023) · Nutrients · doi:10.3390/nu16010034 · Cited by 49
Shankar, R. R., Zeitler, P., Deeb, A., Jalaludin, M. Y., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13279 · Cited by 31
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Functional Alterations of Intestinal P-Glycoprotein under Diabetic Conditions
Kobori, T., Harada, S., Nakamoto, K., & Tokuyama, S. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00369 · Cited by 36
Akhlaghi, F., Matson, K. L., Mohammadpour, A. H., Kelly, M., & Karimani, A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0472-6 · Cited by 31
Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 30
Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis
Piona, C. A., Mozzillo, E., Tosco, A., Volpi, S., Rosanio, F. M., Cimbalo, C., Franzese, A., Raia, V., Zusi, C., Emiliani, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144149 · Cited by 30
Nadeau, K. J., Mayer‐Davis, E. J., Gubitosi‐Klug, R., Zeitler, P. S., Kahn, S. E., Dabelea, D., & SEARCH, T. (2025) · Diabetes Care · doi:10.2337/dc25-0001 · Cited by 39
Self-citationSato, S., Saisho, Y., Kou, K., Meguro, S., Tanaka, M., Irie, J., Kawai, T., & Itoh, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121988 · Cited by 29
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Bizzotto, R., Jennison, C., Jones, A. G., Kurbasic, A., Tura, A., Kennedy, G., Bell, J. D., Thomas, E. L., Frost, G. S., Eriksen, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1567 · Cited by 33
Bi, Y., Tong, G. Y., Yang, H., Cai, M., Ma, J. H., Liang, J., Xin, B., Miao, H., Peng, Z., & Zhu, D. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2443 · Cited by 28
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Takabe, M., Matsuda, T., Hirota, Y., Hashimoto, N., Nakamura, T., Sakaguchi, K., Ogawa, W., & Seino, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.036 · Cited by 27
The 2012 SEMDSA Guideline for the Management of type 2 Diabetes
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872277 · Cited by 39
Fan, Y., Fan, B., Lau, E. S. H., Lim, C. K. P., Wu, H., Ronald, C. W., Ozaki, R., Kong, A. P. S., Chow, E., Luk, A. O. Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110954 · Cited by 28
Bacha, F. F., Cheng, P., Gal, R. L., Kollman, C., Tamborlane, W. V., KLINGENSMITH, G. J., Manseau, K., Wood, J., & Beck, R. W. (2017) · Hormone Research in Paediatrics · doi:10.1159/000481687 · Cited by 25
Ekström, N., Svensson, A., Miftaraj, M., Sundell, K. A., Cederholm, J., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000059 · Cited by 25
Lu, Y., Ma, D., Xu, W., Shao, S., & Yu, X. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12246 · Cited by 25
Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.354 · Cited by 33
Interactions between genetic background, insulin resistance and β‐cell function
Kahn, S. E., Suvag, S., Wright, L. A.-C., & Utzschneider, K. M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01650.x · Cited by 28
Self-citationGrancini, V., Trombetta, M., Lunati, M. E., Boselli, M. L., Gatti, S., Donato, M. F., Palmieri, E., Resi, V., Pugliese, G., Bonadonna, R. C., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.015 · Cited by 23
Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index
Faulenbach, M. V., Wright, L. A.-C., Lorenzo, C., Utzschneider, K. M., Goedecke, J. H., Fujimoto, W. Y., Boyko, E. J., McNeely, M. J., Leonetti, D. L., Haffner, S. M., et al. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.09.011 · Cited by 22
Self-citation
Metadata
- Authors
- Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., & and the ADOPT Study Group
- Affiliations
- University of Washington (US)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- San Antonio Texas
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- King's College London (GB)
- University of Oxford (GB)
- Corresponding author
- Kahn, Steven E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1552-1560
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292330
- OpenAlex
- W2111473023
- Cited by
- 249
- References
- 25
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 21 · 2023: 20 · 2022: 11 · 2021: 17 · 2020: 21 · 2019: 11 · 2018: 19 · 2017: 21 · 2016: 19 · 2015: 10 · 2014: 24 · 2013: 18 · 2012: 15
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- rosiglitazone, metformin, glibenclamide, type 2 diabetes, beta-cell function, insulin sensitivity, oral glucose tolerance test, ADOPT trial, thiazolidinediones, sulfonylureas
- MeSH terms
- Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.